Drug Trial Radar · NCT07925216
A Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting Conditions
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Nov 3, 2026
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Triastek, lnc.Industry
- Sponsor type
- Industry
- Collaborators
- Second Affiliated Hospital of Soochow University
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the PK characteristics and relative bioavailability of single oral doses of Budesonide Delayed Release Tablet and Budesonide Delayed Release Capsules in healthy participants, and to compare the formulation similarity of Budesonide Delayed Release Tablet T1 and T2. The main questions it aims to answer are: How do the pharmacokinetic (PK) characteristics and relative bioavailability of Budesonide Delayed Release Tablet T1 (strength: 4 mg) compare with those of Budesonide Delayed Release Capsules R (trade name: Nefecon, strength: 4 mg)? How do the PK characteristics and relative bioavailability of Budesonide Delayed Release Tablet T2 (strength: 16 mg) compare with those of Budesonide Delayed Release Capsules R (trade name: Nefecon, strength: 4 mg)? How similar are the formulations of Budesonide Delayed Release Tablet T1 (strength: 4 mg) and T2 (strength: 16 mg), and how do their relative bioavailabilities compare? Researchers will compare Budesonide Delayed Release Tablet T1 (strength: 4 mg) and T2 (strength: 16 mg) to Budesonide Delayed Release Capsules R (trade name: Nefecon, strength: 4 mg) to see if the tablets work to treat primary immunoglobulin A nephropathy (IgAN). Participants will: Take a single oral dose of Budesonide Delayed Release Tablet T1 (16 mg, given as 4 mg/tablet × 4 tablets), Tablet T2 (16 mg, given as 16 mg/tablet × 1 tablet), or Capsules R (16 mg, given as 4 mg/capsule × 4 capsules) as directed Visit the clinic regularly for checkups and tests Report any medical problems they experience while taking the study drug
Conditions
- IgA Nephropathy (IgAN)
Interventions
Budesonide delayed release tablet 4mgDrug
Test drug T1
Budesonide Delayed Release CapsulesDrug
Reference drug
Budesonide delayed release tablet 16mgDrug
Test drug T2
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: up to 48 hours post-dose
- AUC4-tTime frame: up to 48 hours post-dose
- AUC0-tTime frame: up to 48 hours post-dose
- AUC0-∞Time frame: up to 48 hours post-dose
- TmaxTime frame: up to 48 hours post-dose
- TlagTime frame: up to 48 hours post-dose
- AUC0-4Time frame: up to 4 hours post-dose
- t1/2Time frame: up to 48 hours post-dose
- λzTime frame: up to 48 hours post-dose
- AUC %ExtrapTime frame: up to 48 hours post-dose
- CL/FTime frame: up to 48 hours post-dose
- VZ/FTime frame: up to 48 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.